Eintrag weiter verarbeiten
Buchumschlag von Multimodality Management for Barcelona Clinic Liver Cancer Stage C Hepatocellular Carcinoma
Verfügbar über Open Access

Multimodality Management for Barcelona Clinic Liver Cancer Stage C Hepatocellular Carcinoma

Gespeichert in:

Bibliographische Detailangaben
Zeitschriftentitel: Liver Cancer
Personen und Körperschaften: Choi, Chihwan, Choi, Gi Hong, Kim, Tae Hyun, Tanaka, Masatoshi, Meng, Mao-Bin, Seong, Jinsil
In: Liver Cancer, 3, 2014, 3-4, S. 405-416
Medientyp: E-Article
Sprache: Englisch
veröffentlicht:
S. Karger AG
Schlagwörter:
author_facet Choi, Chihwan
Choi, Gi Hong
Kim, Tae Hyun
Tanaka, Masatoshi
Meng, Mao-Bin
Seong, Jinsil
Choi, Chihwan
Choi, Gi Hong
Kim, Tae Hyun
Tanaka, Masatoshi
Meng, Mao-Bin
Seong, Jinsil
author Choi, Chihwan
Choi, Gi Hong
Kim, Tae Hyun
Tanaka, Masatoshi
Meng, Mao-Bin
Seong, Jinsil
spellingShingle Choi, Chihwan
Choi, Gi Hong
Kim, Tae Hyun
Tanaka, Masatoshi
Meng, Mao-Bin
Seong, Jinsil
Liver Cancer
Multimodality Management for Barcelona Clinic Liver Cancer Stage C Hepatocellular Carcinoma
Oncology
Hepatology
author_sort choi, chihwan
spelling Choi, Chihwan Choi, Gi Hong Kim, Tae Hyun Tanaka, Masatoshi Meng, Mao-Bin Seong, Jinsil 2235-1795 1664-5553 S. Karger AG Oncology Hepatology http://dx.doi.org/10.1159/000343861 <jats:p>This review summarizes the contents of a workshop on multimodality management for Barcelona Clinic Liver Cancer (BCLC) stage C hepatocellular carcinoma (HCC) held on July 6, 2013, under the auspices of the 4th Asia-Pacific Primary Liver Cancer Expert Meeting Scientific Advisory Committee. BCLC stage C HCC represents a varied disease spectrum and, therefore, further stratification of BCLC stage C should be explored. Although sorafenib is currently the standard treatment for BCLC stage C HCC, the survival benefits are modest and new treatment strategies are still needed. Based on the opinions of Asian experts, there are numerous alternative options aside from sorafenib for the treatment of BCLC stage C HCC, including surgical resection, hepatic arterial infusion chemotherapy, transarterial chemoembolization, and external radiotherapy. Moreover, there are several studies on the multimodality management of BCLC stage C HCC, mainly in the form of retrospective studies and a few phase I and II trials. Multimodality management with combinations of various locoregional therapies or locoregional therapies with systemic targeted therapy using sorafenib needs to be actively investigated. The Asia-Pacific clinical practice guidelines on multimodality management for BCLC stage C HCC need recommendations based on the level of evidence, the strength of the data, and the strength of recommendations of previously reported systems.</jats:p> Multimodality Management for Barcelona Clinic Liver Cancer Stage C Hepatocellular Carcinoma Liver Cancer
doi_str_mv 10.1159/000343861
facet_avail Online
Free
finc_class_facet Medizin
format ElectronicArticle
fullrecord blob:ai-49-aHR0cDovL2R4LmRvaS5vcmcvMTAuMTE1OS8wMDAzNDM4NjE
id ai-49-aHR0cDovL2R4LmRvaS5vcmcvMTAuMTE1OS8wMDAzNDM4NjE
institution DE-D275
DE-Bn3
DE-Brt1
DE-Zwi2
DE-D161
DE-Gla1
DE-Zi4
DE-15
DE-Pl11
DE-Rs1
DE-105
DE-14
DE-Ch1
DE-L229
imprint S. Karger AG, 2014
imprint_str_mv S. Karger AG, 2014
issn 1664-5553
2235-1795
issn_str_mv 1664-5553
2235-1795
language English
mega_collection S. Karger AG (CrossRef)
match_str choi2014multimodalitymanagementforbarcelonacliniclivercancerstagechepatocellularcarcinoma
publishDateSort 2014
publisher S. Karger AG
recordtype ai
record_format ai
series Liver Cancer
source_id 49
title Multimodality Management for Barcelona Clinic Liver Cancer Stage C Hepatocellular Carcinoma
title_unstemmed Multimodality Management for Barcelona Clinic Liver Cancer Stage C Hepatocellular Carcinoma
title_full Multimodality Management for Barcelona Clinic Liver Cancer Stage C Hepatocellular Carcinoma
title_fullStr Multimodality Management for Barcelona Clinic Liver Cancer Stage C Hepatocellular Carcinoma
title_full_unstemmed Multimodality Management for Barcelona Clinic Liver Cancer Stage C Hepatocellular Carcinoma
title_short Multimodality Management for Barcelona Clinic Liver Cancer Stage C Hepatocellular Carcinoma
title_sort multimodality management for barcelona clinic liver cancer stage c hepatocellular carcinoma
topic Oncology
Hepatology
url http://dx.doi.org/10.1159/000343861
publishDate 2014
physical 405-416
description <jats:p>This review summarizes the contents of a workshop on multimodality management for Barcelona Clinic Liver Cancer (BCLC) stage C hepatocellular carcinoma (HCC) held on July 6, 2013, under the auspices of the 4th Asia-Pacific Primary Liver Cancer Expert Meeting Scientific Advisory Committee. BCLC stage C HCC represents a varied disease spectrum and, therefore, further stratification of BCLC stage C should be explored. Although sorafenib is currently the standard treatment for BCLC stage C HCC, the survival benefits are modest and new treatment strategies are still needed. Based on the opinions of Asian experts, there are numerous alternative options aside from sorafenib for the treatment of BCLC stage C HCC, including surgical resection, hepatic arterial infusion chemotherapy, transarterial chemoembolization, and external radiotherapy. Moreover, there are several studies on the multimodality management of BCLC stage C HCC, mainly in the form of retrospective studies and a few phase I and II trials. Multimodality management with combinations of various locoregional therapies or locoregional therapies with systemic targeted therapy using sorafenib needs to be actively investigated. The Asia-Pacific clinical practice guidelines on multimodality management for BCLC stage C HCC need recommendations based on the level of evidence, the strength of the data, and the strength of recommendations of previously reported systems.</jats:p>
container_issue 3-4
container_start_page 405
container_title Liver Cancer
container_volume 3
format_de105 Article, E-Article
format_de14 Article, E-Article
format_de15 Article, E-Article
format_de520 Article, E-Article
format_de540 Article, E-Article
format_dech1 Article, E-Article
format_ded117 Article, E-Article
format_degla1 E-Article
format_del152 Buch
format_del189 Article, E-Article
format_dezi4 Article
format_dezwi2 Article, E-Article
format_finc Article, E-Article
format_nrw Article, E-Article
_version_ 1792334667126407168
geogr_code not assigned
last_indexed 2024-03-01T14:31:54.008Z
geogr_code_person not assigned
openURL url_ver=Z39.88-2004&ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fvufind.svn.sourceforge.net%3Agenerator&rft.title=Multimodality+Management+for+Barcelona+Clinic+Liver+Cancer+Stage+C+Hepatocellular+Carcinoma&rft.date=2014-01-01&genre=article&issn=1664-5553&volume=3&issue=3-4&spage=405&epage=416&pages=405-416&jtitle=Liver+Cancer&atitle=Multimodality+Management+for+Barcelona+Clinic+Liver+Cancer+Stage+C+Hepatocellular+Carcinoma&aulast=Seong&aufirst=Jinsil&rft_id=info%3Adoi%2F10.1159%2F000343861&rft.language%5B0%5D=eng
SOLR
_version_ 1792334667126407168
author Choi, Chihwan, Choi, Gi Hong, Kim, Tae Hyun, Tanaka, Masatoshi, Meng, Mao-Bin, Seong, Jinsil
author_facet Choi, Chihwan, Choi, Gi Hong, Kim, Tae Hyun, Tanaka, Masatoshi, Meng, Mao-Bin, Seong, Jinsil, Choi, Chihwan, Choi, Gi Hong, Kim, Tae Hyun, Tanaka, Masatoshi, Meng, Mao-Bin, Seong, Jinsil
author_sort choi, chihwan
container_issue 3-4
container_start_page 405
container_title Liver Cancer
container_volume 3
description <jats:p>This review summarizes the contents of a workshop on multimodality management for Barcelona Clinic Liver Cancer (BCLC) stage C hepatocellular carcinoma (HCC) held on July 6, 2013, under the auspices of the 4th Asia-Pacific Primary Liver Cancer Expert Meeting Scientific Advisory Committee. BCLC stage C HCC represents a varied disease spectrum and, therefore, further stratification of BCLC stage C should be explored. Although sorafenib is currently the standard treatment for BCLC stage C HCC, the survival benefits are modest and new treatment strategies are still needed. Based on the opinions of Asian experts, there are numerous alternative options aside from sorafenib for the treatment of BCLC stage C HCC, including surgical resection, hepatic arterial infusion chemotherapy, transarterial chemoembolization, and external radiotherapy. Moreover, there are several studies on the multimodality management of BCLC stage C HCC, mainly in the form of retrospective studies and a few phase I and II trials. Multimodality management with combinations of various locoregional therapies or locoregional therapies with systemic targeted therapy using sorafenib needs to be actively investigated. The Asia-Pacific clinical practice guidelines on multimodality management for BCLC stage C HCC need recommendations based on the level of evidence, the strength of the data, and the strength of recommendations of previously reported systems.</jats:p>
doi_str_mv 10.1159/000343861
facet_avail Online, Free
finc_class_facet Medizin
format ElectronicArticle
format_de105 Article, E-Article
format_de14 Article, E-Article
format_de15 Article, E-Article
format_de520 Article, E-Article
format_de540 Article, E-Article
format_dech1 Article, E-Article
format_ded117 Article, E-Article
format_degla1 E-Article
format_del152 Buch
format_del189 Article, E-Article
format_dezi4 Article
format_dezwi2 Article, E-Article
format_finc Article, E-Article
format_nrw Article, E-Article
geogr_code not assigned
geogr_code_person not assigned
id ai-49-aHR0cDovL2R4LmRvaS5vcmcvMTAuMTE1OS8wMDAzNDM4NjE
imprint S. Karger AG, 2014
imprint_str_mv S. Karger AG, 2014
institution DE-D275, DE-Bn3, DE-Brt1, DE-Zwi2, DE-D161, DE-Gla1, DE-Zi4, DE-15, DE-Pl11, DE-Rs1, DE-105, DE-14, DE-Ch1, DE-L229
issn 1664-5553, 2235-1795
issn_str_mv 1664-5553, 2235-1795
language English
last_indexed 2024-03-01T14:31:54.008Z
match_str choi2014multimodalitymanagementforbarcelonacliniclivercancerstagechepatocellularcarcinoma
mega_collection S. Karger AG (CrossRef)
physical 405-416
publishDate 2014
publishDateSort 2014
publisher S. Karger AG
record_format ai
recordtype ai
series Liver Cancer
source_id 49
spelling Choi, Chihwan Choi, Gi Hong Kim, Tae Hyun Tanaka, Masatoshi Meng, Mao-Bin Seong, Jinsil 2235-1795 1664-5553 S. Karger AG Oncology Hepatology http://dx.doi.org/10.1159/000343861 <jats:p>This review summarizes the contents of a workshop on multimodality management for Barcelona Clinic Liver Cancer (BCLC) stage C hepatocellular carcinoma (HCC) held on July 6, 2013, under the auspices of the 4th Asia-Pacific Primary Liver Cancer Expert Meeting Scientific Advisory Committee. BCLC stage C HCC represents a varied disease spectrum and, therefore, further stratification of BCLC stage C should be explored. Although sorafenib is currently the standard treatment for BCLC stage C HCC, the survival benefits are modest and new treatment strategies are still needed. Based on the opinions of Asian experts, there are numerous alternative options aside from sorafenib for the treatment of BCLC stage C HCC, including surgical resection, hepatic arterial infusion chemotherapy, transarterial chemoembolization, and external radiotherapy. Moreover, there are several studies on the multimodality management of BCLC stage C HCC, mainly in the form of retrospective studies and a few phase I and II trials. Multimodality management with combinations of various locoregional therapies or locoregional therapies with systemic targeted therapy using sorafenib needs to be actively investigated. The Asia-Pacific clinical practice guidelines on multimodality management for BCLC stage C HCC need recommendations based on the level of evidence, the strength of the data, and the strength of recommendations of previously reported systems.</jats:p> Multimodality Management for Barcelona Clinic Liver Cancer Stage C Hepatocellular Carcinoma Liver Cancer
spellingShingle Choi, Chihwan, Choi, Gi Hong, Kim, Tae Hyun, Tanaka, Masatoshi, Meng, Mao-Bin, Seong, Jinsil, Liver Cancer, Multimodality Management for Barcelona Clinic Liver Cancer Stage C Hepatocellular Carcinoma, Oncology, Hepatology
title Multimodality Management for Barcelona Clinic Liver Cancer Stage C Hepatocellular Carcinoma
title_full Multimodality Management for Barcelona Clinic Liver Cancer Stage C Hepatocellular Carcinoma
title_fullStr Multimodality Management for Barcelona Clinic Liver Cancer Stage C Hepatocellular Carcinoma
title_full_unstemmed Multimodality Management for Barcelona Clinic Liver Cancer Stage C Hepatocellular Carcinoma
title_short Multimodality Management for Barcelona Clinic Liver Cancer Stage C Hepatocellular Carcinoma
title_sort multimodality management for barcelona clinic liver cancer stage c hepatocellular carcinoma
title_unstemmed Multimodality Management for Barcelona Clinic Liver Cancer Stage C Hepatocellular Carcinoma
topic Oncology, Hepatology
url http://dx.doi.org/10.1159/000343861